Novartis Bioventures Ltd 3
3 · Akouos, Inc. · Filed Jun 25, 2020
Insider Transaction Report
Form 3
Akouos, Inc.AKUS
Novartis Bioventures Ltd
10% Owner
Holdings
- (indirect: See Footnote)
Series B Preferred Stock
→ Common Stock (199,996 underlying) - (indirect: See Footnote)
Series A Preferred Stock
→ Common Stock (856,262 underlying)
Footnotes (3)
- [F1]The Series A Preferred Stock is convertible into Common Stock on a 21.073-for-1 basis into the number of shares of Common Stock as shown in Column 3 without payment of further consideration, at any time at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- [F2]Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
- [F3]The Series B Preferred Stock is convertible into Common Stock on a 21.073-for-1 basis into the number of shares of Common Stock as shown in Column 3 without payment of further consideration, at any time at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.